alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp : A maltohexaose hexasaccharide consisting of five alpha-D-glucopyranose residues and a D-glucopyranose residue joined in sequence by (1->4) glycosidic bonds. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 439606 |
| CHEBI ID | 143182 |
| SCHEMBL ID | 21752778 |
| MeSH ID | M0066640 |
| Synonym |
|---|
| 34620-77-4 |
| maltohexaose , |
| C01936 |
| maltohexaose, >=65% (hplc) |
| amylohexaose |
| alpha-d-glcp-(1->4)-alpha-d-glcp-(1->4)-alpha-d-glcp-(1->4)-alpha-d-glcp-(1->4)-alpha-d-glcp-(1->4)-d-glcp |
| d-maltohexaose |
| wurcs=2.0/2,6,5/[a2122h-1x_1-5][a2122h-1a_1-5]/1-2-2-2-2-2/a4-b1_b4-c1_c4-d1_d4-e1_e4-f1 |
| alpha-d-glucopyranosyl-(1->4)-alpha-d-glucopyranosyl-(1->4)-alpha-d-glucopyranosyl-(1->4)-alpha-d-glucopyranosyl-(1->4)-alpha-d-glucopyranosyl-(1->4)-d-glucopyranose |
| glc(a1-4)glc(a1-4)glc(a1-4)glc(a1-4)glc(a1-4)glc |
| CHEBI:143182 |
| alpha-d-gluco-hexopyranosyl-(1->4)-alpha-d-gluco-hexopyranosyl-(1->4)-alpha-d-gluco-hexopyranosyl-(1->4)-alpha-d-gluco-hexopyranosyl-(1->4)-alpha-d-gluco-hexopyranosyl-(1->4)-d-gluco-hexopyranose |
| AKOS024319624 |
| maltohexanose, dp6 |
| W-202419 |
| AC-34522 |
| mfcd00083650 |
| SCHEMBL21752778 |
| OCIBBXPLUVYKCH-LIGGPISVSA-N |
| amylohexaose and d-maltohexaose |
| Class | Description |
|---|---|
| maltohexaose hexasaccharide | A glucohexaose comprised of six D-glucose residues connected by alpha(1->4) linkages. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (8.86) | 18.7374 |
| 1990's | 13 (16.46) | 18.2507 |
| 2000's | 35 (44.30) | 29.6817 |
| 2010's | 21 (26.58) | 24.3611 |
| 2020's | 3 (3.80) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 80 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||